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In vivo depletion of CD25+ cells prior to LRAST
increases therapeutic efficacy in a murine
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Lymphodepletion, immune reconstitution and active-
specific tumor cell vaccination (LRAST) have proven to
benefit the activation of tumor-specific T cells in mice
during homeostatic proliferation. Immunoregulatory
mechanisms like the induction of regulatory T cells may
counteract this beneficial effect. To further clarify the
role of regulatory T cells (Treg) during LRAST, we
inhibited CD25+ cells in donor mice and/or in recipient
mice in vivo, using the monoclonal anti-CD25 antibody
PC61. We investigated the induction of an anti-tumor
immune response by analyzing tumor growth and the
induction of tumor-specific T cells following LRAST.
C57BL/6 recipient mice were pre-treated with a mono-
clonal anti-CD25 antibody (PC61, 250µg i.p.) or a corre-
sponding isotype control (anti-bGal, 260µg, i.p.) twice
before tumor inoculation with murine melanoma cells
(D5, 5x104 cells s.c.). Three days later, lymphopenia was
induced by injection of cyclophosphamide (200 mg/kg).
The next day, mice were reconstituted with spleen cells
from a congenic mouse strain (C57BL6-Ly5.1, 2x107 cells
i.v.) either pre-treated with anti-CD25 or the isotype anti-
body. The effect of the anti-CD25 antibody on CD45+CD4
+CD25+Foxp3+ (Treg) levels in the peripheral blood was
analyzed by flow cytometry. Tumor growth was monitored
and the induction of tumor-specific T cells was analyzed
by IFN-g cytokine release assay.
Three of five (60%) of the mice treated with anti-CD25
antibody and reconstituted with spleen cells from Treg-
depleted donor mice showed a prolonged survival in
comparison to mice treated with isotype antibody and
reconstituted with spleen cells from naïve donors. Treg-
depleted hosts reconstituted with cells from donor mice
treated with an isotype control showed the highest release
of tumor-specific IFN-g in tumor-draining lymph node
cells. Interestingly, reconstitution with anti-CD25-
depleted spleen cells significantly reduced tumor-specific
IFN-g release in tumor-draining lymph node cells.
Treg inactivation with anti-CD25 antibody prior to
LRAST increases therapeutic efficacy. These results sug-
gest that CD25 depletion of the host, but not of the donor,
is advantageous for the induction of a tumor-specific
immune response. Whether this treatment protocol results
in a therapeutic immune response and further improves
survival is currently under investigation.
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